Drug Trial Radar · NCT04514653
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
146
Actual
Start
Aug 25, 2020
Primary completion
Oct 13, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- REGENXBIO Inc.
- First posted
- Aug 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). The typical treatment for nAMD is frequent injections of anti-VEGF therapy. Researchers are testing ABBV-RGX-314 to see if it has similar effects as the current approved standard of care, such as Lucentis® or Eylea® injections. The duration of this study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314 after week 52, up to 80 weeks post-randomization. The primary outcome measure for this investigational study is to evaluate the mean change in best-corrected visual acuity (BCVA) for ABBV-RGX-314 compared with ranibizumab monthly at the Week 40 visit.
Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
RanibizumabBiological
Ranibizumab (anti-VEGF agent)
ABBV-RGX-314 Dose 1Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
ABBV-RGX-314 Dose 2Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
ABBV-RGX-314 Dose 3Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
Local SteroidDrug
Local steroid
Topical SteroidDrug
Topical steroid
ABBV-RGX-314 Dose 4Genetic
AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) scoreTime frame: 40 weeks
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Retinal Research Institute /ID# 255925
Phoenix, Arizona
California Retina Consultants - Bakersfield /ID# 255910
Bakersfield, California
Retina Vitreous Assoc Med Grp /ID# 255921
Beverly Hills, California
Retinal Diagnostic Center /ID# 272275
Campbell, California
Northern California Retina Vitreous Associates Medical Group, Inc /ID# 255920
Mountain View, California
Retina Consultants of San Diego /ID# 255911
Poway, California
California Retina Consultants - Santa Barbara /ID# 255923
Santa Barbara, California
Southeast Retina Center /ID# 255912
Augusta, Georgia
Springfield Clinic - First /ID# 272274
Springfield, Illinois
Johns Hopkins Hospital /ID# 255919
Baltimore, Maryland
Ophthalmic Consultants of Boston /ID# 255917
Boston, Massachusetts
Sierra Eye Associates /ID# 255908
Reno, Nevada
Eye Associates of New Mexico /ID# 255915
Albuquerque, New Mexico
Duke University Medical Center /ID# 267646
Durham, North Carolina
Mid Atlantic Retina /ID# 255906
Philadelphia, Pennsylvania
Charles Retina Institute /ID# 255922
Germantown, Tennessee
Tennessee Retina - Nashville /ID# 255918
Nashville, Tennessee
Retina Consultants - The Woodlands /ID# 255924
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.